Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Isoprenoid biosynthesis in multiple sclerosis.

G Steen, H Axelsson, M Bowallius

    Acta Neurologica Scandinavica
    |September 1, 1985
    PubMed
    Summary

    Multiple sclerosis (MS) may involve impaired ubiquinone biosynthesis, as indicated by decreased serum ubiquinone levels in patients. This finding suggests a potential metabolic defect in MS, distinct from other isoprenoid pathways.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The value of "diaphragmatic relaxing incision" for the durability of the crural repair in patients with paraesophageal hernia: a double blind randomized clinical trial.

    Frontiers in surgery·2023
    Same author

    Treatment Challenges When Stopping Denosumab.

    Irish medical journal·2022
    Same author

    Incidence of cardiac events in hypertensive men related to adaptive behavior in stressful encounters.

    International journal of behavioral medicine·2005
    Same author

    Relationship between MNA and SF-36 in a free-living elderly population aged 70 to 75.

    The journal of nutrition, health & aging·2005
    Same author

    Rates of metabolism of chlorzoxazone, dextromethorphan, 7-ethoxycoumarin, imipramine, quinidine, testosterone and verapamil by fresh and cryopreserved rat liver slices, and some comparisons with microsomes.

    Toxicology in vitro : an international journal published in association with BIBRA·2003
    Same author

    Is blood pressure at 68 an independent predictor of cognitive decline at 81? Results from follow-up study "Men born in 1914", Malmö, Sweden.

    Aging & mental health·2003

    Area of Science:

    • Biochemistry
    • Neuroscience
    • Metabolic Disorders

    Background:

    • Recent findings suggest a potential defect in isoprenoid metabolism in multiple sclerosis (MS).
    • Urinary metabolites have indicated possible disruptions in the mevalonate pathway in MS patients.
    • Previous studies have explored various metabolic aspects of MS, but ubiquinone's role remains less defined.

    Purpose of the Study:

    • To investigate the role of ubiquinone biosynthesis in the context of multiple sclerosis.
    • To examine serum ubiquinone levels and their relationship with disease status and other biochemical markers in MS.
    • To determine if isoprenoid metabolism defects in MS extend to ubiquinone production.

    Main Methods:

    • Analysis of urinary metabolites to identify potential metabolic defects.

    Related Experiment Videos

  • Measurement of lymphocyte HMG-CoA reductase activity.
  • Assessment of lymphocyte biosynthesis of key isoprenoids (geraniol, farnesol, squalene) from mevalonolactone.
  • Quantification of dolichol levels in MS and control brain white matter.
  • Measurement of serum ubiquinone levels in MS patients (active and stable) and controls, correlating with age and cholesterol.

    • Main Results:

    • Lymphocyte HMG-CoA reductase activity and biosynthesis of geraniol, farnesol, and squalene were unaffected in MS.
    • Dolichol levels in MS brain white matter were comparable to controls.
    • Serum ubiquinone levels were decreased in multiple sclerosis patients, irrespective of disease activity.
    • Serum ubiquinone levels showed age-dependency and correlation with serum cholesterol.
    • A reduced ubiquinone-cholesterol ratio was observed in MS patients.

    Conclusions:

    • The findings suggest a specific deficiency in ubiquinone biosynthesis in multiple sclerosis.
    • The defect appears localized to ubiquinone production rather than broader isoprenoid metabolism.
    • Reduced serum ubiquinone may serve as a potential biomarker or indicator of metabolic dysfunction in MS.